Cancer supportive care is associated with care given to the patients suffering from various types of cancer. Supportive care is intended for relieving suffering of the patients and improving their quality of life.
The global Cancer Supportive Care Products Market was estimated to account for US$ 27,244. Mn in terms of value by the end of 2019.
Global Cancer Supportive Care Products Market: Drivers
Availability of effective cancer supportive care products is expected to propel growth of the global cancer supportive care products market over the forecast period. For instance, according to a study presented at the recent Digital International Liver Congress (ILC 2020), Stivarga (regorafenib) and Opdivo (nivolumab), when administered as second-line treatments, equally improve survival for people with hepatocellular carcinoma (HCC), the most common type of liver cancer.
Global Cancer Supportive Care Products Market: Opportunities
R&D in drug delivery in cancer pain care is expected to offer lucrative growth opportunities for players in the global cancer supportive care products market. For instance, in August 2020, a study by Center for Pain and Supportive Care in Phoenix, Arizona, U.S., supported the use of intrathecal drug delivery in cancer pain care.
Global Cancer Supportive Care Products Market: Restraints
Rising cost of R&D is expected to hinder growth of the global cancer supportive care products market. A new study ‘Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018’, published in March 2020 estimated that the median cost of getting a new drug into the market was US$ 985 million.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2013
The global cancer supportive care products market was valued at US$ 27,244.1 Mn in 2019 and is forecast to reach a value of US$ 40,884.0 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.Increseing prevalence of cancer in developing and developed economies is expected to drive the market growth during the forecast period.
Erythropoietin Stimulating Agents segment held dominant position in the global cancer supportive care products market in 2019, accounting for 24.7% share in terms of value, increasing research and development along with product approvals is expected to assist the segment growth during the forecast period.
Emergence of COVID‐19 has impacted cancer supportive care. For instance, the French Society of Pediatric Oncology, in September 2020, reported that, in a survey, out of the 12 centers that managed COVID‐19 patients, eight centers declared having postponed a specific oncologic treatment because of suspected or confirmed infection. Eight centers (28.6%) declared facing health care providers’ absenteeism because of infection.
Launch of cancer care quality improvement model is expected to propel growth of the global cancer supportive care products market over the forecast period. For instance, in August 2020, a quality improvement tool called “Improving Care Coordination: A Model for Lung Cancer” was released by the Association of Community Cancer Centers (ACCC).The model framework can be used by cancer care providers to improve care coordination for patients with lung cancer who are covered by Medicaid.
Regulations (EU) - Cancer Supportive Care
Cancer drugs are licensed in the EU by the EMA and their various regulatory aspects can be found under directives 2001/83/EC, CPMP/EWP/83561/2005, CPMP/EWP/2330/99 and others
EMA also recommends understanding the drug-drug interactions assessment, mass-balance studies related to pharmacokinetics of cancer-supportive drugs
Assessment of drug-drug interaction are also strongly recommended under directive CPMP/EWP/560/95/Rev.1
Browse Research Report: https://www.coherentmarketinsights.com/market-insight/cancer-supportive-care-drugs-market-2013
Special instructions from EMA and EFPIA for development of products to be used for cancer supportive care
Clinical efficacy measurement of the drug should strongly be inclined towards adequacy of management of nausea and vomiting – even if delayed
Acronyms and tables detailing nausea and vomiting symptoms, along with their pathophysiology should be well documented
There needs to be more emphasis on understanding the carryover effect between controlling chemotherapy induced emesis symptoms. As such, the EFPIA has recommended randomization of at least one drug approval trial
Further, it is inappropriate to mention only one drug as a standard therapy e.g. NK1 receptor antagonist as a standard antiemetic therapy. It is better from the ethical standpoint to mention comparable drug data form the research perspective
Global Cancer Supportive Care Products Market: Competitive Landscape
Major players operating in the global cancer supportive care products market include, Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.
Global Cancer Supportive Care Products Market: Key Developments
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, For instance, in August 2020, G1 Therapeutics Inc. received the U.S. FDA’s priority review designation to a new drug application (NDA) for trilaciclib for the treatment of patients with small cell lung cancer (SCLC) who are being treated with chemotherapy.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2013
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737